Hemab Therapeutics Holdings, Inc. (COAG) Stock Statistics & Valuation Metrics

Hemab Therapeutics Holdings, Inc. has a market cap or net worth of $2.21B. The enterprise value is $0.00.

Hemab Therapeutics Holdings, Inc. has 46,705,410 shares outstanding. The number of shares has decreased by -2.65% in one year.

Hemab Therapeutics Holdings, Inc.’s return on equity (ROE) is 0.36 and return on invested capital (ROIC) is -37.82%.

The current PE Ratio of Hemab Therapeutics Holdings, Inc. is ―. Hemab Therapeutics Holdings, Inc.’s PEG ratio is 0.00.

In the last 12 months, Hemab Therapeutics Holdings, Inc. had revenue of 0.00 and earned -63.91M in profits. Earnings per share was -2.33.

In the last 12 months, operating cash flow was -21.58M and capital expenditures -112.00K, giving a free cash flow of -21.70M billion.

Hemab Therapeutics Holdings, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Hemab Therapeutics Holdings, Inc. upcoming earnings date is May 21, 2026, TBA (Confirmed).

Hemab Therapeutics Holdings, Inc. as a current ratio of 18.03, with Debt / Equity ratio of -0.69%

In the past 12 months, Hemab Therapeutics Holdings, Inc. has paid -227.00K in taxes.

Hemab Therapeutics Holdings, Inc. EV to EBITDA ratio is -12.12, with an EV/FCF ratio of -13.76.

Hemab Therapeutics Holdings, Inc. has $163.53M in cash and marketable securities with $1.06M in debt, giving a net cash position of $162.47M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Hemab Therapeutics Holdings, Inc. is $50.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy